Etveza 25

Etveza 25 Dosage/Direction for Use

etanercept

Manufacturer:

Mega Lifesciences

Distributor:

Metro Drug
Full Prescribing Info
Dosage/Direction for Use
Posology and method of administration: Etanercept treatment should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis. Patients treated with Etanercept should be given the Patient Alert Card.
Posology: Rheumatoid arthritis: 25 mg Etanercept administered twice weekly is the recommended dose. Alternatively, 50 mg administered once weekly has been shown to be safe and effective.
Ankylosing spondylitis: The recommended dose is 25 mg Etanercept administered twice weekly, or 50 mg administered once weekly.
Available data suggest that a clinical response is usually achieved within 12 weeks of treatment. Continued therapy should be carefully reconsidered in a patient not responding within this time period.
Plaque psoriasis: The recommended dose of Etanercept is 25 mg administered twice weekly or 50 mg administered once weekly. Alternatively, 50 mg given twice weekly may be used for up to 12 weeks followed, if necessary, by a dose of 25 mg twice weekly or 50 mg once weekly. Treatment with Etanercept should continue until remission is achieved, for up to 24 weeks. Continuous therapy beyond 24 weeks may be appropriate for some adult patients. Treatment should be discontinued in patients who show no response after 12 weeks. If re-treatment with Etanercept is indicated, the same guidance on treatment duration should be followed. The dose should be 25 mg twice weekly or 50 mg once weekly.
Special Populations: Renal and hepatic impairment: No dose adjustment is required.
Elderly: No dose adjustment is required. Posology and administration are the same as for adults 18-64 years of age.
Method of Administration: Etanercept is administered by subcutaneous injection. The injection sites could be thighs, abdomen and upper arms.
Etanercept is reconstituted with 1 mL WFI before use. The solution should be colorless or light yellow, clear and transparent. The reconstituted solution could be stored at 2-8°C in confined environment for 72 hours.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in